CN100346817C - Chinese medicine composition for preventing and treating hypertension, hyperlipemia and hyperglycemia - Google Patents
Chinese medicine composition for preventing and treating hypertension, hyperlipemia and hyperglycemia Download PDFInfo
- Publication number
- CN100346817C CN100346817C CNB2004100097588A CN200410009758A CN100346817C CN 100346817 C CN100346817 C CN 100346817C CN B2004100097588 A CNB2004100097588 A CN B2004100097588A CN 200410009758 A CN200410009758 A CN 200410009758A CN 100346817 C CN100346817 C CN 100346817C
- Authority
- CN
- China
- Prior art keywords
- radix
- chinese medicine
- medicine composition
- group
- hypertension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses a traditional Chinese medicine composition. The composition is mainly prepared from raw milkvetch root, red sage root, rehmannia root, wolfberry fruit, kudzuvine root, corn stigma, gastrodia tuber, raw hawthorn, semen cassia and lalang grass rhizome. The Chinese medicine composition can be a capsule, a pill, a tablet, oral liquid, etc. The present invention has the efficacy of regulating blood pressure, lowering blood fat and lowering blood sugar, and can be used for preventing and treating hypertension, hyperlipemia and hyperglycemia.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, is a kind of Chinese medicine composition that is used to prevent and treat hypertension, hyperlipidemia, hyperglycemia specifically.
Background technology
Along with deepening continuously of China's reform and opening-up, people's living standard generally improves, and quality of life obviously improves.Meanwhile, the people that affluence is got up are more and more higher to the requirement of body-care on the one hand, and the sickness rate of primary diseases such as incident on the other hand diabetes, cardiovascular disease, cancer is also more and more higher.According to statistics, China every year is about 2,600,000 because of the murderous number of cardiovascular and cerebrovascular disease, on average per hour dead 300 people, and cardiovascular and cerebrovascular disease death person has accounted for first of whole disease cause of the death.The expert points out: hyperlipidemia, hypertension, hyperglycemia are the arch-criminals who causes cardiovascular and cerebrovascular disease such as apoplexy, heart disease, and now the ratio suffered from simultaneously of hyperlipidemia, hypertension, hyperglycemia get up high more, and get up unusual trouble of treatment.
At present, depressor on the market has nifedipine, nitrendipine, captopril, hydrochlorothiazide, Propranolol etc., lipid lowerers is mainly Statins, as: visit sthene, lipitor etc., antidiabetic drug has acarbose, metformin, gliclazide, glipizide, voglibose etc., and they are many can only controlling symptoms, and very big side effect is arranged, time one, long human body promptly developed immunity to drugs, so patient's Chinese medicine of seeking help in many ways.
Traditional Chinese medical theory thinks, the Therapeutic Principle of " three-hypers disease " should " take stopgap measures earlier, then effect a permanent cure ", starts with from eliminating evil earlier, and then give and setting upright, and can take into account and rule together according to the primary and secondary of deficiency and excess specimen in case of necessity.The Chinese patent medicine of listing blood pressure lowering is arranged No. 0, lipid level, diabetes pill, snow source health etc. at present also have some to be in clinical stage, as hypoglycemic and thirst-relieving capsule, XUEFU ZHUYU JIAONANG etc.
By the retrieval to prior art, not finding is having the Chinese medicine composition similar and/or identical with the present invention.The inventor sums up by animal experiment and clinical observation, thereby has finished the present invention.
Summary of the invention
The purpose of this invention is to provide a kind of Chinese medicine composition that is used to prevent and treat hypertension, hyperlipidemia, hyperglycemia.
The invention provides a kind of Chinese medicine composition that is used to prevent and treat hypertension, hyperlipidemia, hyperglycemia.It is made up of effective ingredient and/or pharmaceutically acceptable carrier, it is characterized in that: it is to be made by following raw materials by weight proportions: Radix Astragali 10-50 part, Radix Salviae Miltiorrhizae 1-50 part, Radix Rehmanniae 1-50 part, Fructus Lycii 1-50 part, Radix Puerariae 1-50 part, Stigma Maydis 1-50 part, Rhizoma Gastrodiae 1-50 part, Fructus Crataegi 1-50 part, Semen Cassiae 1-50 part, Rhizoma Imperatae 1-50 part.
Wherein preferred, Radix Astragali 10-35 part, Radix Salviae Miltiorrhizae 15-30 part, Radix Rehmanniae 10-28 part, Fructus Lycii 5-20 part, Radix Puerariae 17-35 part, Stigma Maydis 15-30 part, Rhizoma Gastrodiae 1-18 part, Fructus Crataegi 15-30 part, Semen Cassiae 12-23 part, Rhizoma Imperatae 10-25 part.
Wherein said Radix Salviae Miltiorrhizae can substitute with Radix Rubiae, and the wherein said Radix Rehmanniae can substitute with Pheretima, and wherein said Radix Puerariae can substitute with Radix Asparagi.
Chinese medicine composition of the present invention can be made various common formulations together with its effective ingredient and/or acceptable accessories, as capsule, tablet, pill, oral liquid etc.
The present invention has the effect of blood pressure regulation, blood fat reducing, blood sugar lowering, can be used for prevention and treatment hypertension, hyperlipidemia, hyperglycemia.
Specific embodiment
Embodiment 1: the preparation of tablet of the present invention
Take by weighing the following raw materials in weight medicine: Radix Astragali 50g, Radix Salviae Miltiorrhizae 35g, Radix Rehmanniae 15g, Fructus Lycii 45g, Radix Puerariae 50g, Stigma Maydis 10g, Rhizoma Gastrodiae 50g, Fructus Crataegi 35g, Semen Cassiae 35g, Rhizoma Imperatae 1g; Radix Astragali, Radix Salviae Miltiorrhizae, the Radix Rehmanniae, Fructus Lycii, Radix Puerariae, Stigma Maydis, Rhizoma Gastrodiae, Fructus Crataegi, Semen Cassiae, Rhizoma Imperatae are carried out preliminary working; The medicine that then processing is cooked drops into multi-function extractor, the water that adds 3-10 times of drug weight, heat and decoct boiling back 25 minutes to 3 hours after-filtration of slow fire for the first time, the water that adds for the second time 3-10 times of drug weight, back 25 minutes to 3 hours after-filtration seethe with excitement, the same for the third time, after three times three filtered medicine liquid being dropped into vacuum concentrator concentrates, after concentrating, extract to drop in the jacketed pan and carry out water evaporates, put into the heated drying case again, temperature in the drying baker is controlled between the 40-70 degree, take out after 5-8 hour, planar, again through pulverizing, sieve, add adjuvant (starch, PVP etc.) making granule, is slabbing after the tablet machine compression.
Embodiment 2: the preparation of pill of the present invention
Take by weighing the following raw materials in weight medicine: Radix Astragali 10g, Radix Salviae Miltiorrhizae 45g, Radix Rehmanniae 1g, Fructus Lycii 1g, Radix Puerariae 45g, Stigma Maydis 50g, Rhizoma Gastrodiae 15g, Fructus Crataegi 50g, Semen Cassiae 50g, Rhizoma Imperatae 10g; Radix Astragali, Radix Salviae Miltiorrhizae, the Radix Rehmanniae, Fructus Lycii, Radix Puerariae, Stigma Maydis, Rhizoma Gastrodiae, Fructus Crataegi, Semen Cassiae, Rhizoma Imperatae are carried out preliminary working; The medicine that then processing cooked is pulverized, is sieved, and sterilizes again, put in right amount at last the Mel of perfecting mix the back pill.
Embodiment 3: the preparation of capsule of the present invention
Take by weighing the following raw materials in weight medicine: Radix Astragali 25g, Radix Salviae Miltiorrhizae 1g, Radix Rehmanniae 50g, Fructus Lycii 30g, Radix Puerariae 1g, Stigma Maydis 45g, Rhizoma Gastrodiae 15g, Fructus Crataegi 45g, Semen Cassiae 45g, Rhizoma Imperatae 30g; Radix Astragali, Radix Salviae Miltiorrhizae, the Radix Rehmanniae, Fructus Lycii, Radix Puerariae, Stigma Maydis, Rhizoma Gastrodiae, Fructus Crataegi, Semen Cassiae, Rhizoma Imperatae are carried out preliminary working; The medicine that then processing is cooked drops into multi-function extractor, the water that adds 3-10 times of drug weight, heat and decoct boiling back 25 minutes to 3 hours after-filtration of slow fire for the first time, the water that adds for the second time 3-10 times of drug weight, back 25 minutes to 3 hours after-filtration seethe with excitement, the same for the third time, after three times three filtered medicine liquid being dropped into vacuum concentrator concentrates, after concentrating, extract to drop in the jacketed pan and carry out water evaporates, put into the heated drying case again, temperature in the drying baker is controlled between the 40-70 degree, take out after 5-8 hour, planar, again through pulverizing, sieve, add adjuvant (starch, PVP etc.) make granule, above-mentioned granule pack in the hungry area softgel shell capsule.
Embodiment 4: the preparation of oral liquid of the present invention
Take by weighing the following raw materials in weight medicine: Radix Astragali 45g, Radix Salviae Miltiorrhizae 50g, Radix Rehmanniae 20g, Fructus Lycii 50g, Radix Puerariae 10g, Stigma Maydis 50g, Rhizoma Gastrodiae 15g, Fructus Crataegi 15g, Semen Cassiae 1g, Rhizoma Imperatae 50g; Radix Astragali, Radix Salviae Miltiorrhizae, the Radix Rehmanniae, Fructus Lycii, Radix Puerariae, Stigma Maydis, Rhizoma Gastrodiae, Fructus Crataegi, Semen Cassiae, Rhizoma Imperatae are boiled decocting three times, filter, merging filtrate concentrates, and adds sweeting agent Mel and diluent water and makes oral liquid.
Embodiment 5: the preparation of tablet of the present invention
According to embodiment 1 described method, difference is to select following raw materials in weight for use: Radix Astragali 10g, Radix Rubiae 15g, Radix Rehmanniae 10g, Fructus Lycii 15g, Radix Puerariae 20g, Stigma Maydis 1g, Rhizoma Gastrodiae 5g, Fructus Crataegi 15g, Semen Cassiae 20g, Rhizoma Imperatae 10g.
Embodiment 6: the preparation of pill of the present invention
According to embodiment 2 described methods, difference is to select following raw materials in weight for use: Radix Astragali 35g, Radix Salviae Miltiorrhizae 21g, Pheretima 15g, Fructus Lycii 5g, Radix Puerariae 17g, Stigma Maydis 30g, Rhizoma Gastrodiae 1g, Fructus Crataegi 30g, Semen Cassiae 12g, Rhizoma Imperatae 12g.
Embodiment 7: the preparation of capsule of the present invention
According to embodiment 3 described methods, difference is to select following raw materials in weight for use: Radix Astragali 25g, Radix Salviae Miltiorrhizae 30g, Radix Rehmanniae 28g, Fructus Lycii 20g, Radix Asparagi 35g, Stigma Maydis 20g, Rhizoma Gastrodiae 18g, Fructus Crataegi 24g, Semen Cassiae 23g, Rhizoma Imperatae 25g.
Embodiment 8: the preparation of oral liquid of the present invention
According to embodiment 4 described methods, difference is to select following raw materials in weight for use: Radix Astragali 23g, Radix Salviae Miltiorrhizae 20g, Radix Rehmanniae 28g, Fructus Lycii 5g, Radix Puerariae 23g, Stigma Maydis 26g, Rhizoma Gastrodiae 1g, Fructus Crataegi 24g, Semen Cassiae 13g, Rhizoma Imperatae 22g.
Below set forth the effect of this Chinese medicine composition by test.
Experimental example 1:
1 materials and methods
1.1 material: alloxan: Sigma company produces; The glucose oxidase enzyme reagent kit: Shanghai Rongsheng Bioisystech Co., Ltd produces; The WFZ800D ultraviolet-uisible spectrophotometer: second optical instrument factory, Beijing makes.
1.2 the foundation of experimental diabetic animal model
Male Wistar rat, body weight 200～250g, 8 of picked at random are made diabetes models for 60 as the normal control group.Fasting be can't help after the water 24h, dosage lumbar injection alloxan by 120mg/kg on the firstth, 90mg/kg on the secondth, the normal control group is with the normal saline of method injection equivalent, 72h measures each Mus fasting blood sugar after administration on the secondth, and the rat that the screening blood glucose value surpasses 11.1mmol/L is the diabetes experimental group.
1.3 the grouping of diabetes rat and treatment
Rat is divided into insoral group (irritating stomach insoral 75mg/kgd) at random, the large, medium and small dosage group of oral liquid of the present invention (is irritated stomach, dosage is followed successively by 40g/kgd, 20g/kgd, 10g/kgd), the diabetic model group normal saline of equivalent (irritate stomach), the normal control group is irritated the normal saline of stomach equivalent equally.Administration is taken a blood sample after 7 days and is measured fasting glucose and carbohydrate tolerance.
1.4 sample collecting and mensuration
Rat after water 5h is can't help in fasting, tail vein blood, the centrifugal 15min of 3500r/min, separation of serum is as sample.
1. the mensuration of blood glucose value: adopt glucose oxidase method;
2. the mensuration of carbohydrate tolerance: adopt glucose oxidase method.Measure rat 0.5h, 1h, 2h blood glucose value oral glucose 2.5g/kg after, and trace blood glucose value change curve in time with fasting blood sugar blood glucose when zero.With area under the approximate trapezoid method calculated curve.
1.5 all data of statistical procedures represent that with x ± s using in groups, paired t-test compares.
2 results
The rat blood sugar value of (before being administration) is compared with the normal control group after the modeling all has significant difference (P＜0.05), after the administration under the blood glucose value of insoral positive controls, 3 dosage groups and the glucose tolerance curve area compare with diabetic model group significant difference (P＜0.05) all arranged, the results are shown in Table 1.
Table 1 oral liquid of the present invention is to the influence of blood glucose in diabetic rats value and carbohydrate tolerance
| Group | Dosage (gkg -1· d -1) | Blood glucose value (mmolL -1) | Area (mmolhL under the glucose tolerance curve -1) | |
| Before the administration | After the administration | |||
| Dosage group small dose group in the heavy dose of group of Normal group diabetic model group phenformin group | Physiological saline physiological saline 0.075 40 20 10 | 4.32±1.56 19.37± 5.13# 18.37± 2.12# 20.22± 4.57# 19.23± 3.78# 19.93± 8.80# | 4.27±1.37 22.54± 8.35# 13.21± 5.35 * 13.97± 6.32 * 14.13± 5.17 * 14.26± 5.25 * | 14.27±1.58 51.34±13.27# 32.37±9.54 * 35.31±10.21 * 37.38±9.14 * 40.17±6.52 * |
*P＜0.05 is with the diabetic model group comparison same period; #P＜0.05 is with the normal control group comparison same period
3. conclusion
Large, medium and small three the dosage groups of Chinese medicine oral liquid cause the rat hyperglycemia to alloxan the obvious functions of blood sugar effect.
Experimental example 2:
1 materials and methods
11 materials: streptozotocin: Sigma company produces; The glucose oxidase enzyme reagent kit: Shanghai Rongsheng Bioisystech Co., Ltd produces; The WFZ800D ultraviolet-uisible spectrophotometer: second optical instrument factory, Beijing makes
1.2 the foundation of experimental diabetic animal model
Male Wistar rat, body weight 200～250g, 8 of picked at random are made diabetes models for 60 as the normal control group.Fasting be can't help after the water 24h, press the dosage tail vein injection streptozotocin of 60mg/kg, the normal control group is with the normal saline of method injection equivalent, and 72h measures each Mus fasting blood sugar after administration on the secondth, and the rat that the screening blood glucose value surpasses 11.1mmol/L is the diabetes experimental group.
1.3 the grouping of diabetes rat and treatment
Rat is divided into insoral group (irritating stomach insoral 75mg/kgd) at random, the large, medium and small dosage group of oral liquid of the present invention (is irritated stomach, dosage is followed successively by 40g/kgd, 20g/kgd, 10g/kgd), the diabetic model group normal saline of equivalent (irritate stomach), the normal control group is irritated the normal saline of stomach equivalent equally.Administration is taken a blood sample after 7 days and is measured fasting glucose and carbohydrate tolerance.
1.4 sample collecting and mensuration
Rat after water 5h is can't help in fasting, tail vein blood, the centrifugal 15min of 3500r/min, separation of serum is as sample.
1. the mensuration of blood glucose value: adopt glucose oxidase method;
2. the mensuration of carbohydrate tolerance: adopt glucose oxidase method.Measure rat 0.5h, 1h, 2h blood glucose value oral glucose 2.5g/kg after, and trace blood glucose value change curve in time with fasting blood sugar blood glucose when zero.With area under the approximate trapezoid method calculated curve.
1.5 all data of statistical procedures represent that with x ± s using in groups, paired t-test compares.
2 results
The rat blood sugar value of (before being administration) is compared with the normal control group after the modeling all has significant difference (P＜0.05), after the administration under the blood glucose value of insoral positive controls, 3 dosage groups and the glucose tolerance curve area compared significant difference (P＜0.05 in various degree with diabetic model group, P＜0.01), the results are shown in Table 1.
Table 1 oral liquid of the present invention is to streptozotocin induced hyperglycemia rat blood sugar value and carbohydrate tolerance
Influence
| Group | Dosage (gkg -1· d -1) | Blood glucose value (mmolL -1) | Area (mmolhL under the glucose tolerance curve -1) | |
| Before the administration | After the administration | |||
| Dosage group small dose group in the heavy dose of group of Normal group diabetic model group phenformin group | Physiological saline physiological saline 0.075 40 20 10 | 3.97±2.01 19.36± 2.78# 20.12± 3.54# 18.96± 5.16# 19.17± 4.28# 20.56± 4.38# | 4.18±1.69 20.17± 5.24# 15.51± 4.28 * 14.27± 5.11 * 15.25± 6.64 * 16.27± 4.12 * | 18.24±2.18 58.76±14.15# 30.52±10.17 * 32.56±9.97 * 39.54±4.21 * 37.58±7.54 * |
*P＜0.05 is with the diabetic model group comparison same period; #P＜0.05 is with the normal control group comparison same period
3. conclusion
Large, medium and small three the dosage groups of Chinese medicine oral liquid cause the rat hyperglycemia to streptozotocin the obvious functions of blood sugar effect.
Experimental example 3:
Case is selected
Diagnostic criteria
The Evaluation of Diagnostic Criteria of Hypertension that this test is adopted is the diagnostic criteria of four hypertension guides of WHO/ISH in 1999, sees following table for details:
Evaluation of Diagnostic Criteria of Hypertension
| Systolic pressure (mmHg) | Diastolic pressure (mmHg) | |
| Ideal bp | ＜120 | ＜80 |
| Normal arterial pressure | ＜130 | ＜85 |
| Normal high value | 130-139 | 85-89 |
| Hypertension I level (slightly) | 140-159 | 90-99 |
| Subgroup: borderline hypertension | 140-149 | 90-94 |
| Hypertension II level (moderate) | 160-179 | 100-109 |
| Hypertension III level (severe) | ≥180 | ≥110 |
| Isolated systolic hypertension subgroup: critical systolic hypertension | ≥140 140-149 | ＜90 ＜90 |
Hypertension is standard by stages:
I phase hypertension: blood pressure reaches the hypertension level of making a definite diagnosis, and clinically is not in the mood for, brain, kidney complication shower
II phase hypertension: blood pressure reaches makes a definite diagnosis the hypertension level, and a following person is arranged:
X line, electrocardiogram or ultrasonic examination are seen left ventricular hypertrophy, examination of ocular fundus sees that the optical fundus tremulous pulse is arranged is general or limitation narrows down, (106-177mmol/L), ultrasonic or X line will have atherosclerotic plaque to urine protein or/and creatinine concentration of plasma slightly raises
III phase hypertension: blood pressure reaches makes a definite diagnosis the hypertension level, the clinical manifestation of organ injury occurs:
The heart: angina pectoris, myocardial infarction, heart failure
Brain: transient ischemic attack, apoplexy, hypertensive encephalopathy
Optical fundus: retinal hemorrhage, ooze out companion or do not accompany papilloedema
Kidney: more than the serum creatinine 177mmol/L, renal failure
Blood vessel: interlayer hemangioma, arteriosclerosis obliterans
Include standard in
Meet above-mentioned hypertension Western medicine diagnose standard and tcm syndrome (yin deficiency syndrome) diagnostic criteria
With II phase hypertension is the object of observation
Essential hypertension, not 3 pressure measurement on the same day in 1 week, blood pressure reaches diagnostic criteria
Not medication, or take hypertension drug but after two weeks of drug withdrawal
Exclusion standard
Age is at under-18s or over-65s, gestation or women breast-feeding their children
Secondary hypertension
Merge to have the inclination, serious primary disease, psychotics such as brain, liver, kidney and hemopoietic system
Allergic constitution or to multiple drug allergy person
This tests selected case situation
This test MethodsThe cases enrolled 226 examples, male 147 examples, women 79 examples; Age 20-62 year; Be associated with atherosis 62 examples of peripheral arterial, be associated with slightly rising person's 35 examples of plasma creatinine, person's 104 examples that are associated with the left ventricular hypertrophy are associated with the optical fundus tremulous pulse person of narrowing down 25 examples; I level hypertension 72 examples, II level hypertension 136 examples, III level hypertension 18 examples.
Observational technique
Health giving quality observation
Main related symptoms and relevant sign
Dizzy, headache, soreness of waist and knee, cardiopalmus, insomnia, forgetful, tinnitus, dysphoria with smothery sensation, the few tongue of red tongue, stringy and thready pulse and count
Coherence check
Monitoring of blood pressure, Electrocardioscopy
Safety observation
General health check-up item inspection and blood, urine, just conventional.The heart, liver, kidney function test.
Grouping and method of administration
Case 226 examples are included in this test in, are divided into 2 groups at random, are respectively treatment group of the present invention and positive controls, every group 113 example.Wherein:
Treatment group: take oral liquid of the present invention, every day 3 times, each 62g
Matched group: take lotensin, each 10-20mg, every day 1 time
The efficacy determination method
1) produce effects: more than the diastolic pressure decline 10mmHg, and reach normal range; Descended though diastolic pressure is not reduced to normally 20mmHg or more than
2) effective: diastolic pressure descends not as good as 10mmHg, but has reached normal range; Diastolic pressure is the preceding decline 10-19mmHg of treatment, but does not reach normal range; Systolic pressure is handed over more than the preceding decline 30mmHg of treatment.(possessing above-mentioned one)
3) invalid: as not reach above standard person
The result
Case 226 examples are included in this test in, all finish test
Blood pressure situation before and after the treatment the results are shown in Table 1
The situation of change of blood pressure before and after table 1 the present invention and the lotensin treatment hyperpietic medication
| Grouping | The example number | Systolic pressure (mmHg) | Diastolic pressure (mmHg) | |
| The treatment group | After treating before the treatment | 113 | 163.5±14.7 135.7±13.4 ** | 101.4±10.2 82.5±5.8 ** |
| Matched group | After treating before the treatment | 113 | 161.3±13.2 140.2±15.3 ** | 98.6±9.5 79.6±8.8 ** |
*P＜0.01 is with treatment is relatively preceding on the same group
As seen from the above table, relatively, each organizes pressure value all has significance to descend (P＜0.01) before and after two groups of treatments, and the same treatment period of the identical index with matched group of treatment group is unknown significance difference (P＞0.05) relatively.
Efficacy of antihypertensive treatment is estimated situation, the results are shown in Table 2
Therapeutic evaluation situation before and after table 2 the present invention and the lotensin treatment hyperpietic medication
| Grouping | The example number | Produce effects | Effectively | Invalid | Total effective rate (%) |
| Treatment group matched group | 113 113 | 67 59 | 29 33 | 7 11 | 96 92 |
As seen from the above table, the antihypertensive effect after two groups of treatments relatively, unknown significance difference (P＞0.05).Simultaneously, clinical observation hypertension related symptoms and sign all improve significantly.
The safety testing result
With routine blood test, the routine urinalysis of two groups of experimenters before and after testing, just conventional darling renal function index is carried out statistical analysis, between two groups and the data before and after two groups of tests significant difference (P＞0.05) does not all appear.More also there is no unusual after the medication before patient's general health check-up project and the treatment.
Conclusion
Safety of the present invention is good.
The present invention can effectively treat hypertension, and related symptoms all has clear improvement, and total effective rate can reach more than 90%.
Experimental example 4:
Data and method
Case is selected
Diagnostic criteria
The Western medicine diagnose standard that this test is adopted is Chinese cardiovascular diseases's magazine editorial board's dyslipidemia Preventing Countermeasures special topic group " dyslipidemia control suggestion " standard in 1997, be specially: lipid examination: under the normal diet situation, detect the blood lipid level of fasting after 12-14 hour, when judging whether to have hyperlipidemia, must have 1-2 at least 2 blood specimen detection record meanings judgements in week:
Serum total cholesterol (TC)＞5.72mmol/L
Triglyceride (TG)＞1.70mmol/L
Low density lipoprotein, LDL (LDL-C)＞3.64mmol/L
High density lipoprotein (HDL-C)＜0.91mmol/L
Include standard in
Meet above-mentioned hypertension Western medicine diagnose standard and tcm syndrome (yin deficiency syndrome) diagnostic criteria
The constitutional hyperlipidemia
Though take fat-reducing medicament, single more than 2 weeks of drug withdrawal, and blood lipid level still meets diagnostic criteria.
Exclusion standard
Gestation or women breast-feeding their children
Once suffered from beyond acute myocardial infarction, the cerebrovascular in half a year, patient behind severe trauma or the capital operation
The Secondary cases hyperlipemic patients
The drug-induced hyperlipemia and the subtype hypercholesterolemiapatients patients of isozygotying
Using heparin, thyroxine therapy medicine and other to influence the patient of blood lipid metabolism medicine
Merge to have the inclination, serious primary disease, psychotics such as brain, liver, kidney and hemopoietic system
This tests selected case situation
This test MethodsThe cases enrolled 186 examples, male 109 examples, women 77 examples; 49 years old mean age.
Observational technique
Health giving quality observation
Main related symptoms and relevant sign
Dizzy, headache, soreness of waist and knee, cardiopalmus, insomnia, forgetful, tinnitus, dysphoria with smothery sensation, the few tongue of red tongue, stringy and thready pulse and count
Main physico-chemical examination index
The assay of TC, TG, LDL-C, HDL-C
Safety observation
General health check-up item inspection and blood, urine, just conventional.The heart, liver, kidney function test.
Grouping and method of administration
Case 186 examples are included in this test in, are divided into 2 groups at random, are respectively treatment group of the present invention and positive controls, every group 93 example.Wherein:
Treatment group: take the present invention, every day 3 times, each 62g.
Matched group: take lovastatin, every day 1 time, each 20mg.
The efficacy determination method
Produce effects: lipids detection reaches each person
TC descends 〉=20%; TG descends 〉=40%; HDL-C rising 〉=0.26mmol/L;
TC-HDL-C/HDL-C descends 〉=20%
Effectively: lipids detection reaches each person
TC descend 〉=10% but＜20%; TG descend 〉=20% but＜40%; HDL-C rise 〉=0.104 but＜0.26mmol/L; TC-HDL-C/HDL-C descend 〉=10% but＜20%
Invalid: as not reach above standard person
The result
Case 186 examples are included in this test in, all finish test
Blood Lipid situation before and after the treatment the results are shown in Table 1
Blood Lipid feelings before and after table 1 oral liquid of the present invention and the medication of lovastatin treatment hyperlipemic patients
Condition (mmol/L, x ± s)
| Grouping | The example number | TC | TG | HDL-C | LDL-C | |
| The treatment group | After treating before the treatment | 93 | 6.82±1.75 5.32± 1.26 ** | 2.73±0.98 1.98± 0.76 ** | 1.21±0.48 1.86± 0.72 ** | 3.59±1.24 2.17± 0.99 ** |
| Matched group | After treating before the treatment | 93 | 6.29±2.04 5.27± 2.13 ** | 2.88±1.21 2.03± 1.19 ** | 1.07±0.59 1.13±0.66 | 3.84±1.31 3.02± 1.54 ** |
*P＜0.01 is with treatment is relatively preceding on the same group
As seen from the above table, treatment group treatment front and back relatively TC, TG, LDL-C value all have significance to descend (P＜0.01), and the HDL-C value has significance rising (P＜0.01); Relatively TC, TG, LDL-C value all have significance decline (P＜0.01) before and after the treatment of control group.
Blood fat reducing therapeutic evaluation situation the results are shown in Table 2
Therapeutic evaluation situation before and after table 2 the present invention and the medication of lovastatin treatment hyperlipemic patients
| Grouping | The example number | Produce effects | Effectively | Invalid | Total effective rate (%) |
| Treatment group matched group | 93 93 | 71 58 | 18 26 | 4 9 | 89 84 |
As seen from the above table, the lipid-lowering effect after two groups of treatments relatively, unknown significance difference (P＞0.05).Simultaneously, clinical observation hyperlipidemia related symptoms and sign all improve significantly.
The safety testing result
With routine blood test, the routine urinalysis of two groups of experimenters before and after testing, just conventional darling renal function index is carried out statistical analysis, between two groups and the data before and after two groups of tests significant difference (P＞0.05) does not all appear.More also there is no unusual after the medication before patient's general health check-up project and the treatment.
Conclusion
Safety of the present invention is good.
The present invention can effectively treat hyperlipemia, and related symptoms all has clear improvement, and total effective rate can reach 89%.
Claims (6)
1, a kind of Chinese medicine composition that is used to prevent and treat hypertension, hyperlipidemia, hyperglycemia, it is made up of effective ingredient and pharmaceutically acceptable carrier, it is characterized in that: made by following raw materials by weight proportions: Radix Astragali 10-50 part, Radix Salviae Miltiorrhizae 1-50 part, Radix Rehmanniae 1-50 part, Fructus Lycii 1-50 part, Radix Puerariae 1-50 part, Stigma Maydis 1-50 part, Rhizoma Gastrodiae 1-50 part, Fructus Crataegi 1-50 part, Semen Cassiae 1-50 part, Rhizoma Imperatae 1-50 part.
2, Chinese medicine composition according to claim 1 is characterized in that: made by following raw materials by weight proportions: Radix Astragali 10-35 part, Radix Salviae Miltiorrhizae 15-30 part, Radix Rehmanniae 10-28 part, structure Qi 5-20 part, Radix Puerariae 17-35 part, Stigma Maydis 15-30 part, Rhizoma Gastrodiae 1-18 part, Fructus Crataegi 15-30 part, Semen Cassiae 12-23 part, Rhizoma Imperatae 10-25 part.
3, Chinese medicine composition according to claim 1 and 2, wherein said Radix Salviae Miltiorrhizae can substitute with Radix Rubiae.
4, Chinese medicine composition according to claim 1 and 2, the wherein said Radix Rehmanniae can substitute with Pheretima.
5, Chinese medicine composition according to claim 1 and 2, wherein said Radix Puerariae can substitute with Radix Asparagi.
6, Chinese medicine composition according to claim 1 and 2, it is capsule, pill, tablet, oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100097588A CN100346817C (en) | 2004-11-08 | 2004-11-08 | Chinese medicine composition for preventing and treating hypertension, hyperlipemia and hyperglycemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2004100097588A CN100346817C (en) | 2004-11-08 | 2004-11-08 | Chinese medicine composition for preventing and treating hypertension, hyperlipemia and hyperglycemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1772208A CN1772208A (en) | 2006-05-17 |
| CN100346817C true CN100346817C (en) | 2007-11-07 |
Family
ID=36759460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2004100097588A Expired - Fee Related CN100346817C (en) | 2004-11-08 | 2004-11-08 | Chinese medicine composition for preventing and treating hypertension, hyperlipemia and hyperglycemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100346817C (en) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101143180B (en) * | 2006-09-12 | 2011-06-29 | 石药集团中奇制药技术（石家庄）有限公司 | Medicine for treating diabetes |
| CN101116504B (en) * | 2007-08-24 | 2010-09-29 | 河南省泷鑫医药保健品有限公司 | Health products for reducing blood fat and method for preparing the same |
| CN101480472B (en) * | 2008-01-09 | 2012-02-29 | 石河子大学 | Medicament for reducing blood pressure and regulating blood fat and production method |
| CN102716471A (en) * | 2012-07-03 | 2012-10-10 | 童长虹 | Anti-hyperlipidemia health-care product |
| CN104782848A (en) * | 2015-05-11 | 2015-07-22 | 广西梧州茂圣茶业有限公司 | Liubao (Chinese character) tea-containing composition with hypoglycemic function |
| CN105106838A (en) * | 2015-08-28 | 2015-12-02 | 安徽省颍上县中医院 | Traditional Chinese medicine combination for treating hyperlipidemia |
| CN105168981A (en) * | 2015-10-22 | 2015-12-23 | 河南金贵元生物科技有限公司 | Medicinal-edible homologous composition for treating three-highs (hypertension, hyperglycemia and hyperlipidaemia) and anhypnia and preparation method thereof |
| CN105326936A (en) * | 2015-12-04 | 2016-02-17 | 河南明德科润医药科技有限责任公司 | Traditional Chinese medicine composition for treating hypertension and hyperlipidemia and preparation method thereof |
| CN108114130A (en) * | 2018-02-02 | 2018-06-05 | 重庆跃龙生物制药有限公司 | Treat Chinese medicine composition of hypertension and hyperlipidemia and preparation method thereof |
| CN108904713B (en) * | 2018-10-08 | 2021-07-16 | 云南中医学院 | Chinese medicine for treating cardiovascular disease |
| CN109331122A (en) * | 2018-12-10 | 2019-02-15 | 李晓屏 | A kind of disperse blood stasis and dredge collateral pill side and its preparation process |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1328839A (en) * | 2001-06-06 | 2002-01-02 | 王大洋 | Medicine for reducing blood pressure and cleaning fat and its production method |
| CN1336212A (en) * | 2001-08-24 | 2002-02-20 | 王林 | Diabetes treating medicine |
| CN1359717A (en) * | 2001-12-26 | 2002-07-24 | 赵广钧 | Process for prepairng Chinese-medicinal ointment of treating uremia, renal hypertension and hyperlipomia |
| CN1437959A (en) * | 2002-02-10 | 2003-08-27 | 杨志东 | Chinese prepartory for treating cardiovascular and cerebrovascular disease and preparation method |
-
2004
- 2004-11-08 CN CNB2004100097588A patent/CN100346817C/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1328839A (en) * | 2001-06-06 | 2002-01-02 | 王大洋 | Medicine for reducing blood pressure and cleaning fat and its production method |
| CN1336212A (en) * | 2001-08-24 | 2002-02-20 | 王林 | Diabetes treating medicine |
| CN1359717A (en) * | 2001-12-26 | 2002-07-24 | 赵广钧 | Process for prepairng Chinese-medicinal ointment of treating uremia, renal hypertension and hyperlipomia |
| CN1437959A (en) * | 2002-02-10 | 2003-08-27 | 杨志东 | Chinese prepartory for treating cardiovascular and cerebrovascular disease and preparation method |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1772208A (en) | 2006-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100346817C (en) | Chinese medicine composition for preventing and treating hypertension, hyperlipemia and hyperglycemia | |
| CN1457829A (en) | Chinese medicine composition for curing chronic atrophic sastritis and its preparing method and quality control method | |
| CN1628786A (en) | Medicine for treating hyperlipemia | |
| CN1682936A (en) | Medicinal composition for treating hyperlipemia and its preparing method | |
| CN1239183C (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
| CN1565552A (en) | Chinese traditional medicine for treating immune hypofunction and disfunction | |
| CN1917895A (en) | Extracts of houttuynia cordata and rubus coreanus and their composition for preventing and treating allergic diseases | |
| CN1557842A (en) | Process for extracting polygonatum polysaccharides, preparing process for medical preparation and use thereof | |
| CN1698878A (en) | Kidney replenishing medicinal composition and its preparation process and novel use | |
| CN1191082C (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN1813819A (en) | Hedgehog hydnum fruiting body or hyphostroma and culture extract and formulation and preparing method | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN1221280C (en) | Chinese patent drug for treating heart brain blood vessel disease and its preparation method | |
| CN1733089A (en) | Medicine for treating diabetes and its complications and process for preparing the same | |
| CN1290529C (en) | Medicine for treating gout, hyperuricemia and hyperlipemia and preparation method thereof | |
| CN1820770A (en) | Chinese medicine composition for treating apoplexy and its preparing method | |
| CN1562113A (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN1162177C (en) | Medicine for curing fatty liver | |
| CN1222305C (en) | Chinese medicine for treating liver-kidney insufficiency, qi and yin vacuity and its preparation method | |
| CN1742984A (en) | Medicine copmosition, its preparing method and quality control method | |
| CN1300161C (en) | Yellow pigment of safflower preparation method and application | |
| CN1194743C (en) | Chinese medicinal composition for treating atrophic arthritis, preparing method and quality controlling method thereof | |
| CN1634463A (en) | Medicine for treating diabetes and production method thereof | |
| CN101062314A (en) | Medicine for curing gout and its preparing method | |
| CN101062374A (en) | Method for preparing Chinese traditional combination capsule for treating cancer and the product thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |